Category - Markets

Markets

BTIG starts Coya Therapeutics at buy; PT $15

BTIG launched coverage of Coya Therapeutics (NASDAQ:COYA) with a “buy” rating and a $15 price target. The stock closed at $5.76 on May 17. Analyst Thomas Shrader, Ph.D., writes that his price target is based on “our...

May 18, 2023

Markets

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...

May 15, 2023

Markets

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG downgraded Babylon Health (NASDAQ:BBLN) to “sell” from “neutral” with a price target of zero, reflecting concerns around earnings, cash flow and cash needs, and the structure of a possible go-private transaction...

May 11, 2023

Markets

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

BTIG downgraded CareDx (NASDAQ:CDNA) to “neutral” from “buy” and removed its price target. The stock closed at $8.59 on May 10. CareDx is a market leader in blood-based testing for both heart and kidney transplant...

May 11, 2023

Markets

Research Capital bullish on Theralase bladder cancer data

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) data generated to date shows that Ruvidar’s efficacy is “strong and durable” for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and...

May 10, 2023

Markets

Dawson James ups Can-Fite to buy on valuation call

Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...

May 1, 2023

Markets

RJ starts WELL Health at OP; PT $8.50 (Canadian)

Raymond James initiated coverage of WELL Health Technologies (TSX:WELL) with an “outperform” rating and price target of $8.50 (Canadian). The stock closed at $5.46 on April 27. WELL Health operates a hybrid care...

April 28, 2023

Markets

Cantor starts Disc Medicine at OW; PT $45

Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...

April 28, 2023

Markets

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given updated data released in the fourth...

April 27, 2023

Markets

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

Stifel upgraded IDEADYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” and raised its price target to $24 from $18 following additional darovasertib data in uveal melanoma, which revealed an improved mPFS in first-line...

April 24, 2023

Category - Markets

BTIG starts Coya Therapeutics at buy; PT $15

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

Research Capital bullish on Theralase bladder cancer data

Dawson James ups Can-Fite to buy on valuation call

RJ starts WELL Health at OP; PT $8.50 (Canadian)

Cantor starts Disc Medicine at OW; PT $45

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

General

More